Soleno Therapeutics Inc (SLNO) Stock Price, Quote & News

Company Profile

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was i...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 213 8444

Fax: 650 213 8383

Website: soleno.life

Address:

100 Marine Parkway, Suite 400, Redwood City, United States

Hottehueh Oct. 3 at 5:07 PM

$SLNO added some 60/75 dec call spreads. 4x if 75 or above in dec...

0 · Reply

SweepCastApp Oct. 3 at 8:27 AM

$SLNO: Unusual Options Activity Alerted CALL flow observed 172x contracts at Strike price of $75 Exp on 01/16/2026 with Premium of $82K and showing NEUTRAL Sentiment

0 · Reply

heyupikachu1821 Oct. 2 at 8:17 PM

$LQDA $SRPT $SLNO $ABEO $MLTX These are all at extreme lows that I whole heartedly believe they will bounce back from Each has dropped for its own reason. Each comes with its own risk. Each will likely take time to recover But at these prices, the risk / reward is worth considering if you have the patience to go for a longer-term swing

0 · Reply

pcguy2 Oct. 2 at 7:15 PM

$SLNO Doc #1: “he’s close to taking 4/6 patients off due to lack of efficacy and negative risk/benefit given known tolerability concerns.” “Three of his patients have been on XR for at least 3 months…he thinks patient experience has been mixed so far…noted that all his VYKAT XR patients have seen some tolerability issues primarily peripheral edema and hyperglycemia…our doc has not seen any ‘dramatic’ efficacy or sudden change in behavior….” Doc #2 has not put any patients on the drug. “She finds it hard to justify 6 months of use with no efficacy when other health risks may be rising. She noted that pediatric PWS patients don’t experience hyperphagia until age 4–8 years old, and she will have to see more real-world clinical data before prescribing.” Source: Wells Fargo equity research, “Therapeutics KOL Insights Conference Takeaways: Rare Obesities Panel (HO, PWS),” Oct 2, 2025

0 · Reply

Wallst45 Oct. 2 at 4:11 AM

$SLNO company will respond soon. This scorpion is scam

0 · Reply

WrappedLunatic Oct. 2 at 3:48 AM

$SLNO Why do yall buy a stock then are clueless as to why it goes down? Do yall not own any subscription to MarketWatch or know how to Google?? You come here looking for answers lol

2 · Reply

heyupikachu1821 Oct. 1 at 10:19 PM

$SLNO this was insanely disappointing. and as far as I can tell, without reason

0 · Reply

towie Oct. 1 at 8:51 PM

$SLNO why was our stock down so much today? thanks

0 · Reply

StockHunter75 Oct. 1 at 7:18 PM

$SLNO Short this trash 🗑️

0 · Reply

kingeboue Oct. 1 at 2:52 PM

$SLNO what is going on right now?

1 · Reply

Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman

Sep 10, 2025, 7:51 PM EDT - 24 days ago

Soleno Therapeutics, Inc. (SLNO) Under Investigation After Scorpion Capital Report Raises Drug Safety Concerns; Investors Urged to Contact Award-Winning Firm, Gibbs Mura

Sep 10, 2025, 5:23 PM EDT - 24 days ago

SLNO Investors Have Opportunity to Join Soleno Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Sep 10, 2025, 12:57 PM EDT - 24 days ago

Soleno reports death of patient who took genetic disorder treatment, shares fall

Sep 5, 2025, 2:09 AM EDT - 4 weeks ago

Soleno Therapeutics, Inc. (SLNO) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 4, 2025, 5:05 AM EDT - 4 weeks ago

Soleno Therapeutics, Inc. (SLNO) Presents At Cantor Global Healthcare Conference 2025 Transcript

Aug 27, 2025, 8:00 AM EDT - 5 weeks ago

Soleno Therapeutics to Participate in Upcoming September Conferences

Aug 15, 2025, 1:30 PM EDT - 7 weeks ago

Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe

Aug 7, 2025, 3:01 AM EDT - 2 months ago

Soleno Therapeutics, Inc. (SLNO) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:01 PM EDT - 2 months ago

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results

Jul 10, 2025, 9:07 AM EDT - 3 months ago

Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

Jul 10, 2025, 6:01 AM EDT - 3 months ago

Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock

Jul 10, 2025, 6:00 AM EDT - 3 months ago

Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025

Jun 20, 2025, 8:00 AM EDT - 3 months ago

Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference

May 22, 2025, 5:32 PM EDT - 4 months ago

Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome

May 20, 2025, 4:05 PM EDT - 4 months ago

Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome

May 7, 2025, 10:30 PM EDT - 5 months ago

Soleno Therapeutics, Inc. (SLNO) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:01 PM EDT - 5 months ago

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results

Apr 23, 2025, 7:00 AM EDT - 5 months ago

Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET

Apr 14, 2025, 7:00 AM EDT - 6 months ago

Soleno Therapeutics Announces VYKAT(TM) XR Launch

Mar 27, 2025, 8:11 AM EDT - 6 months ago

Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder

Mar 26, 2025, 5:15 PM EDT - 6 months ago

Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

Jan 29, 2025, 4:05 PM EST - 8 months ago

Soleno Therapeutics to Participate in Upcoming February Investor Conferences

Dec 17, 2024, 4:05 PM EST - 10 months ago

Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC

Nov 27, 2024, 8:00 AM EST - 11 months ago

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 8:30 AM EST - 11 months ago

Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Nov 14, 2024, 4:05 PM EST - 11 months ago

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024

Oct 10, 2024, 2:53 PM EDT - 1 year ago

Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

Oct 8, 2024, 6:51 PM EDT - 1 year ago

SLNO Stock Rises as Prader-Willi Treatment Nears FDA Approval

Oct 3, 2024, 12:03 PM EDT - 1 year ago

Janus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics Inc

JHG

Sep 16, 2024, 4:05 PM EDT - 1 year ago

Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Aug 27, 2024, 1:00 PM EDT - 1 year ago

Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Aug 19, 2024, 4:17 PM EDT - 1 year ago

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

May 22, 2024, 4:05 PM EDT - 1 year ago

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

May 22, 2024, 8:00 AM EDT - 1 year ago

Soleno Therapeutics to Participate in Upcoming Investor Conferences

May 15, 2024, 8:00 AM EDT - 1 year ago

Soleno Therapeutics Stands with the Prader-Willi Syndrome Community

May 9, 2024, 4:05 PM EDT - 1 year ago

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 2, 2024, 10:32 PM EDT - 1 year ago

Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock

May 2, 2024, 4:01 PM EDT - 1 year ago

Soleno Therapeutics Announces Proposed Public Offering of Common Stock

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome

Hottehueh Oct. 3 at 5:07 PM

$SLNO added some 60/75 dec call spreads. 4x if 75 or above in dec...

0 · Reply

SweepCastApp Oct. 3 at 8:27 AM

$SLNO: Unusual Options Activity Alerted CALL flow observed 172x contracts at Strike price of $75 Exp on 01/16/2026 with Premium of $82K and showing NEUTRAL Sentiment

0 · Reply

heyupikachu1821 Oct. 2 at 8:17 PM

0 · Reply

pcguy2 Oct. 2 at 7:15 PM

0 · Reply

Wallst45 Oct. 2 at 4:11 AM

$SLNO company will respond soon. This scorpion is scam

0 · Reply

WrappedLunatic Oct. 2 at 3:48 AM

$SLNO Why do yall buy a stock then are clueless as to why it goes down? Do yall not own any subscription to MarketWatch or know how to Google?? You come here looking for answers lol

2 · Reply

heyupikachu1821 Oct. 1 at 10:19 PM

$SLNO this was insanely disappointing. and as far as I can tell, without reason

0 · Reply

towie Oct. 1 at 8:51 PM

$SLNO why was our stock down so much today? thanks

0 · Reply

StockHunter75 Oct. 1 at 7:18 PM

$SLNO Short this trash 🗑️

0 · Reply

kingeboue Oct. 1 at 2:52 PM

$SLNO what is going on right now?

1 · Reply

Quantumup Oct. 1 at 11:52 AM

Stifel⬇️ $SLNO $115 was $118/reit Buy after refreshing its PWS model to reflect recent KOL feedback—still sees pot $2B+ WW rev.. $AARD $RYTM Stifel said: Management remains confident in Vykat's safety and broader risk/benefit profile (i.e., consistent with data/label and known AE-profile), noting feedback from KOLs and patient advocacy groups is positive. Looking ahead, management remains confident in the growth trajectory of Vykat, even as naturally there's some element of a "bolus" here (2Q numbers can't be extrapolated linearly in perpetuity). EU also represents a potential meaningful expansion opportunity next year (similar prevalence numbers; if anything, more concentrated in certain countries). We are also refreshing our PWS market model to reflect our recent KOL feedback (LINK): 50% penetration within the target/addressable population (or 30% of all PWS). This very slightly lowers our estimates but still supports a substantial opportunity ($2B+ WW); our TP goes to $115 (from $118).

0 · Reply

Quantumup Oct. 1 at 10:32 AM

Jones Trading🏁 $AARD Buy/$33 $SLNO $RYTM Jones Trading said: We are initiating coverage of Aardvark Therapeutics (ticker: AARD) with a Buy Rating and $33 PT. Aardvark is a clinical-stage biotech company focused on treating obesity and hyperphagia (excessive eating). The core of Aardvark's portfolio is ARD-101, an oral small molecule agonist of TAS2R, which increases gut-localized secretion of satiety hormones, including GLP-1 and CCK. Jones Trading added:

0 · Reply

SweepCastApp Oct. 1 at 1:32 AM

$SLNO: Unusual Options Activity Alerted CALL flow observed 82x contracts at Strike price of $65 Exp on 01/16/2026 with Premium of $103K and showing BEARISH Sentiment

0 · Reply

highnihilism Sep. 29 at 9:34 PM

$SLNO: 180 trades, $2.4M vs $756K avg (3.2x). Bullish skew: $2.2M calls/$193K puts. 97% single-leg. $POWL: 163 trades, $2.3M vs $915K avg (2.5x). Bullish skew: $2.2M calls/$75K puts. 50% single-leg. $BILI: 1.4K trades, $3.6M vs $2.0M avg (1.8x). Bullish skew: $2.2M calls/$1.5M puts. 82% single-leg. $NTGR: 384 trades, $2.2M vs $93K avg (23.3x). Bullish skew: $2.2M calls/$6K puts. 66% single-leg.

0 · Reply

BioCapitalist99 Sep. 29 at 1:19 PM

$TNXP A Phase II trial in Prader–Willi syndrome is set to begin in the coming months. Earlier this year, $SLNO received approval for a treatment in this indication and is currently valued (ex-cash) at over $3 billion. The total market opportunity for this syndrome is estimated at $2+ billion. This represents a strong long-term catalyst. If early Phase II data next year are positive, the program could emerge as a significant asset, potentially supporting an enterprise value for this only single asset at above $600–800 million range.

0 · Reply

Quantumup Sep. 29 at 11:11 AM

Stifel🏁 $AARD Buy-$24/said: We're initiating coverage of Aardvark with a Buy rating and a $24 target price. Aardvark's ARD-101 represents an under-the-radar, late-stage Prader-Willi (PWS) play with: (1) a unique MOA; (2) a ph2 clinical signal; and (3) a near(ish)-term ph3 readout (3Q26). Now the clinical data and biology are imperfect (par for the course in PWS) and the trial could fail simply by chance (PWS is very challenging). That said, we conducted a deep dive into both the data and biology/mechanism where we're optimistic '101 has a shot-and has a higher POS than shares imply, creating a compelling setup as Vykat validates the PWS opportunity. More specifically—even as we're bullish on Vykat—not everyone will be a candidate/responder: minority share still implies a large opportunity and Vykat's continued success (and any strategic interest it garners) should only benefit '101. Bottom line: it's high-risk/binary, but at a $200MM EV, the risk/reward is heavily upside-biased. $SLNO $RYTM

0 · Reply

SweepCastApp Sep. 29 at 10:16 AM

$SLNO: Unusual Options Activity Alerted PUT flow observed 35x contracts at Strike price of $70 Exp on 12/19/2025 with Premium of $41K and showing BULLISH Sentiment

0 · Reply

StockHunter75 Sep. 26 at 6:16 PM

$SLNO 80+ coming soon

0 · Reply

SweepCastApp Sep. 25 at 8:28 PM

$SLNO: TRADE PUT activity detected 100 @ 2.55, Strike 60.0, Exp 10/17/2025, Premium $25,500, Sentiment BULLISH

0 · Reply

CrispDry Sep. 24 at 11:26 PM

$SLNO if not for the short attack and FUD this would be north of $110

0 · Reply

ignoreo Sep. 24 at 10:59 PM

$PGEN $PHAT $NKTR $SLNO all of these were me closing my entire position my closes need to be studied. also didnt close a single imminent loser besides $REPL

0 · Reply

PhishTourFunds Sep. 24 at 9:33 PM

$SLNO Back to $72

1 · Reply

Market Cap	3.15B
Revenue (ttm)	0.00
Net Income (ttm)	-175.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.21

Volume	1,642,700
Avg Vol	1,942,954
Day's Range	N/A - N/A
Shares Out	53.15M
Stochastic %K	29%
Beta	-2.75
Analysts	Strong Sell
Price Target	$119.30